Home Stock

Stock Research: Laboratorios Farmaceuticos Rovi

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Laboratorios Farmaceuticos Rovi

MCE:ROVI ES0157261019
73
  • Value
    46
  • Growth
    100
  • Safety
    Safety
    92
  • Combined
    94
  • Sentiment
    5
  • 360° View
    360° View
    73
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Laboratorios Farmaceuticos ROVI SA (ROVI) is a Spanish pharmaceutical company focused on the development and commercialization of medicines and drugs. It operates in Diagnostics (contrast mediums), Prescription (Hibor, Osseor, Hepadren, Pneumovax-23, Glufan, Corlentor, Exxiv, Calcio y Vitamina D3 Rovi, Absorcol), and Over The Counter (Perspirex, Enerzona, Dentimelo, ColdPack) fields. ROVI operates nationwide and abroad, with subsidiaries including Gineladius SL, Frosst Iberica SA, Rovi Contract Manufacturing SL, and Bertex Pharma GmbH. In the last fiscal year, the company had 2179 employees, a market cap of $3215 million, profits of $495 million, and revenue of $791 million.

more

ANALYSIS: With an Obermatt 360° View of 73 (better than 73% compared with alternatives), overall professional sentiment and financial characteristics for the stock Laboratorios Farmaceuticos Rovi are above average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Laboratorios Farmaceuticos Rovi. The consolidated Growth Rank has a good rank of 100, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 100% of competitors in the same industry. In addition, the consolidated Safety Rank has a safer rank of 92 which means that the company has a financing structure that is safer than 92% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the consolidated Value Rank has a less desirable rank of 46 which means that the share price of Laboratorios Farmaceuticos Rovi is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is higher than for 54% of alternative stocks in the same industry. The consolidated Sentiment Rank also has a low rank of 5, which means that professional investors are more pessimistic about the stock than for 95% of alternative investment opportunities. ...read more

more
Strongest Rank Sentiment
Weakest Rank Growth
Country Spain
Industry Pharmaceuticals
Size Medium
Website rovi.es
Index
IBEX 35
Laboratorios Farmaceuticos Rovi stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 13-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
46 24 35 42
Growth
100 6 19 95
Safety
Safety
92 93 88 75
Sentiment
5 16 98 46
360° View
360° View
73 15 76 80
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
41 47 70 81
Opinions Change
29 12 69 50
Pro Holdings
n/a 32 90 12
Market Pulse
28 43 83 53
Sentiment
5 16 98 46
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
46 24 35 42
Growth
100 6 19 95
Safety Safety
92 93 88 75
Combined
94 43 38 92
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
49 26 33 40
Price vs. Earnings (P/E)
21 40 38 49
Price vs. Book (P/B)
32 19 22 17
Dividend Yield
63 58 63 72
Value
46 24 35 42
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
71 12 4 74
Profit Growth
53 12 18 92
Capital Growth
96 26 19 31
Stock Returns
80 24 98 96
Growth
100 6 19 95
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
69 80 76 57
Refinancing
74 44 47 42
Liquidity
90 95 100 76
Safety Safety
92 93 88 75

Similar Stocks

Discover high‑ranked alternatives to Laboratorios Farmaceuticos Rovi and broaden your portfolio horizons.

Polski Koncern Naftowy ORLEN Spolka Akcyjna

WSE:PKN
Country: Poland
Industry: Oil & Gas Refining
Size: XX-Large
Full Stock Analysis

Volkswagen VW

GER:VOW
Country: Germany
Industry: Automobile Manufacturers
Size: XX-Large
Full Stock Analysis

Grifols

MCE:GRF
Country: Spain
Industry: Biotechnology
Size: X-Large
Full Stock Analysis

Richter Gedeon

BUD:RICHTER
Country: Hungary
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Frequently Asked
Questions

The company has high growth and safe financing but is expensive (low Value Rank) and has low market sentiment. This is a warning that the stock may be too expensive. This is for an experienced growth investor willing to risk overpaying, but only after conducting thorough research on future growth potential.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews